Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? III. Antagonist's viewpoint.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D006321:Heart / Q000502:physiology; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology*; D006801:Humans; D018377:Neurotransmitter Agents / Q000502:physiology*; D009638:Norepinephrine / Q000097:blood; D005082:Physical Exertion; D011379:Prognosis; D014661:Vasoconstriction
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D018377:Neurotransmitter Agents; D009638:Norepinephrine